Comparison between a fixed-dose contrast protocol and a weight-based contrast dosing protocol in abdominal CT

Effect of patient characteristics on aortic attenuation in iodinated contrast-enhanced Abdominopelvic CT: A retrospective study

INTRODUCTION

Contrast Enhanced Computed Tomography (CECT) abdomen and pelvis is a common imaging procedure. Hospitals typically follow fixed protocols of contrast volume administration for triple-phase CECT abdomen and pelvis scans and have found that patients are either underdosed or overdosed with respect to their body habitus. The aim of the study was to correlate different patient characteristics such as Total body weight (TBW), Lean Body Mass (LBM), Body Mass Index (BMI), Body Surface Area (BSA) and Blood Volume (BV) with aortic enhancement in the arterial and portal venous phases for CECT Abdomen and pelvis.

METHODS

A total of 106 patients who underwent triple-phase CECT abdomen & pelvis were retrospectively studied. A circular region-of-interest (ROI) of 100 mm2 was positioned on descending aorta for unenhanced, arterial, and portal venous phases to measure the aortic enhancement in Hounsfield's units. Measure of contrast attenuation (ΔH) was calculated from the difference of CT values on unenhanced images and contrast images. Correlation analysis was performed to evaluate the relation of patient body characteristics with aortic enhancement.

RESULTS

Correlation analysis revealed that BMI exhibited the least correlation when compared to the other characteristics in both arterial (r = -0.3; p = 0.002) and portovenous phases (r = -0.35; p < 0.001) whereas TBW, LBW, BSA and BV reported moderate inverse correlations. BV was found to be the strongest of all characteristics under linear regression.

CONCLUSION

The study supports the use of protocols that adjust contrast volume to either TBW, LBW, BSA, or BV for CT abdomen and pelvis scan.

IMPLICATION OF PRACTICE

The right body parameter ensures optimal contrast enhancement, improving the visualization of anatomical structures and helps in adapting tailored contrast injection protocols.

More sustainable use of iodinated contrast media - Why?

OBJECTIVES

Based on a narrative review of the literature to 1) assess the need for and 2) report methods to help deliver a sustainable approach to iodinated contrast media (ICM) administration.

KEY FINDINGS

Acute ICM shortages have been noted in the literature. As demand for contrast-enhanced imaging continues to increase and access to raw materials becomes more limited, such events may increase. Evidence from the literature has documented a range of iodinated contrast reduction strategies. These include individualised contrast-media dosing, multi-dose bulk ICM vials, switching to alternative modalities or the increased use of non-contrast examinations. The optimisation of imaging parameters, the use of saline chasers, and alternative contrast agents should be further considered. Given the rising concerns regarding the presence and effects of ICMs in waste and drinking water, further consideration of strategies for managing waste and excreted ICMs are starting to emerge.

CONCLUSIONS

Sustainable ICM practices are needed to help avoid supply shortages and to help protect our environment. Such practices must be led and supported locally, nationally, and internationally. Sustainable ICM practices must be reflected within professional Standards of Proficiencies and be adopted by all members of the multidisciplinary team.

IMPLICATIONS FOR PRACTICE

Changes to working practices surrounding the sustainable use of ICMs will likely become commonplace. New methods to ensure optimised ICM dosage with minimal wastage will be more heavily featured in departmental practices. Correct disposal of waste and excreted ICMs will also form part of future changes to practice.

Decreased portal vein attenuation and liver enhancement with reduced intravenous contrast dosage during the national iodinated contrast shortage of 2022

Objectives

The worldwide shortage of intravenous (IV) Omnipaque iodinated contrast (Iohexol, GE Healthcare; Milwaukee, WI, USA) forced institutions to adopt various policies regarding contrast allocation. We sought to evaluate the impact of our hospital's response to the shortage, which was to decrease the dose of IV contrast from 100 mL to 75 mL for patients weighing between 45.4 and 136 kg (100-300 lbs) undergoing abdominal computed tomography (CT) examinations. The main objective was to assess for any differences in liver attenuation and enhancement between contrast dosages. Secondary outcomes included assessing differences in aortic and portal vein attenuation, the variance in attenuation measurements, and whether radiology reports included the correct IV contrast dose.

Material and Methods

Consecutive CT abdomen or CT abdomen and pelvis examinations without and with contrast were analyzed for the 3 months before the contrast shortage and for 3 months during the contrast shortage. Attenuation in Hounsfield units (HUs) was measured in the liver on pre-contrast and portal venous phase images. Vessel attenuation was measured in the aorta (arterial phase) and main portal vein (portal venous phase). Standard deviation of liver attenuation measurements was recorded as an indicator of signal-to-noise. Liver enhancement was calculated as the difference between liver portal venous phase attenuation and pre-contrast attenuations.

Results

Thirty-nine fixed dose (100 mL) and 36 reduced dose (75 mL) consecutive CT studies were included in the study. There were no significant differences between the two groups with respect to baseline characteristics such as age, weight, body mass index, and gender. There was no significant difference in pre-contrast liver attenuation between groups, but there was statistically significant greater liver attenuation (99.6 vs. 91.2 HU, P = 0.04) and liver enhancement (51.5 vs. 39.1 HU, P < 0.0001) during the portal venous phase for the fixed-dose group compared to the reduced dose group. There was significantly greater main portal vein opacification during the portal venous phase for the fixed dose group (146.6 vs. 122.2 HU, P < 0.0001). No significant difference was found in aortic opacification during the arterial phase (245 vs. 254 HU, P = 0.52). There was no difference in the standard deviation of liver attenuation measurements on the portal venous phase between the groups. The dose was reported correctly in all the patients receiving the fixed dose and in 92% of patients receiving the reduced dose, which was not statistically significant (P = 0.11).

Conclusion

Reducing the IV contrast dose from 100 mL to 75 mL Omnipaque 350 in patients weighing 45.4-136 kg (100-300 lbs) undergoing an abdominal CT examination resulted in significantly decreased portal vein opacification and liver enhancement. In particular, liver enhancement and calculated iodine concentrations fell below suggested thresholds for adequate conspicuity of liver lesions. The change in contrast administration protocol also led to more errors in contrast dose reporting in the radiologist's report. These findings are broadly applicable to many practice settings and can help inform strategies in response to any potential future-iodinated contrast shortage.

Reduced Intravenous Contrast Dose Portal Venous Phase Photon-Counting Computed Tomography Compared With Conventional Energy-Integrating Detector Portal Venous Phase Computed Tomography

OBJECTIVE

The aim of this study was to compare portal venous phase photon-counting CT (PCCT) using 20 cc less than weight-based contrast dosing with energy-integrating detector CT (EID-CT) using weight-based dosing by quantitative and qualitative analysis.

METHODS

Fifty adult patients who underwent a reduced intravenous contrast dose portal venous phase PCCT from May 1, 2023, to August 10, 2023, and a prior portal-venous EID-CT with weight-based contrast dosing were retrospectively identified. Hounsfield units (HU) and noise (SD of HU) were obtained from region-of-interest measurements on 70-keV PCCT and EID-CT in 4 hepatic segments, the main and right portal vein, and both paraspinal muscles. Signal-to-noise and contrast-to-noise ratios were computed. Three abdominal radiologists qualitatively assessed overall image quality, hepatic enhancement, and confidence for metastasis identification on 5-point Likert scales. Readers also recorded the presence/absence of hepatic metastases. Quantitative variables were compared with paired t tests, and multiple comparisons were accounted for with a Bonferroni-adjusted α level of .0016. Ordinal logistic regression was used to evaluate qualitative assessments. Interreader agreement for hepatic metastases was calculated using Fleiss' κ.

RESULTS

Fifty patients (32 women; mean [SD] age, 64 [13] years) were included. There was no significant difference in hepatic HU, portal vein HU, noise, and signal-to-noise or contrast-to-noise ratio between reduced contrast dose portal venous phase PCCT versus EID-CT (all Ps > 0.0016). Image quality, degree of hepatic enhancement, and confidence for metastasis identification were not different for reduced dose PCCT 70-keV images and EID-CT (P = 0.06-0.69). κ Value for metastasis identification was 0.86 (95% confidence interval, 0.70-1.00) with PCCT and 0.78 (95% confidence interval, 0.59-0.98) with EID-CT.

CONCLUSION

Reduced intravenous contrast portal venous phase PCCT 70-keV images had similar attenuation and image quality as EID-CT with weight-based dosing. Metastases were identified with near-perfect agreement in reduced dose PCCT 70-keV images.

Customised weight-based volume contrast media protocol for multiphase abdominal computed tomography

INTRODUCTION

Multiphase computed tomography (CT) using fixed volume contrast media may lead to high radiation exposure and toxicity in patients with low body weight. We evaluated a customised weight-based protocol for multiphase CT in terms of radiation exposure, image quality and cost savings.

METHODS

A total of 224 patients were recruited. An optimised CT protocol was applied using 100 kV and 1 mL/kg of contrast media dosing. The image quality and radiation dose exposure of this CT protocol were compared to those of a standard 120 kV, 80 mL fixed volume protocol. The radiation dose information and CT Hounsfield units were recorded. The signal-to-noise ratio, contrast-to-noise ratio (CNR) and figure of merit (FOM) were used as comparison metrics. The images were assessed for contrast opacification and visual quality by two radiologists. The renal function, contrast media volume and cost were also evaluated.

RESULTS

The median effective dose was lowered by 16% in the optimised protocol, while the arterial phase images achieved significantly higher CNR and FOM. The radiologists' evaluation showed more than 97% absolute agreement with no significant differences in image quality. No significant differences were found in the pre- and post-CT estimated glomerular filtration rate. However, contrast media usage was significantly reduced by 1,680 mL, with an overall cost savings of USD 421 in the optimised protocol.

CONCLUSION

The optimised weight-based protocol is cost-efficient and lowers radiation dose while maintaining overall contrast enhancement and image quality.

The impact of body compositions on contrast medium enhancement in chest CT: a randomised controlled trial

Objective

To compare a fixed-volume contrast medium (CM) protocol with a combined total body weight (TBW) and body composition-tailored protocol in chest CT.

Methods and materials

Patients referred for routine contrast enhanced chest CT were prospectively categorised as normal, muscular or overweight. Patients were accordingly randomised into two groups; Group 1 received a fixed CM protocol. Group 2 received CM volume according to a body composition-tailored protocol. Objective image quality comparisons between protocols and body compositions were performed. Differences between groups and correlation were analysed using t-test and Pearson's r.

Results

A total of 179 patients were included: 87 in Group 1 (mean age, 51 ± 17 years); and 92 in Group 2 (mean age, 52 ± 17 years). Compared to Group 2, Group 1 showed lower vascular attenuation in muscular (mean 346 Hounsfield unit (HU) vs 396 HU; p = 0.004) and overweight categories (mean 342 HU vs 367 HU; p = 0.12), while normal category patients showed increased attenuation (385 vs 367; p = 0.61). In Group 1, strongest correlation was found between attenuation and TBW in muscular (r = -.49, p = 0.009) and waist circumference in overweight patients (r = -.50, p = 0.005). In Group 2, no significant correlations were found for the same body size parameters. In Group 1, 13% of the overweight patients was below 250 HU (p = 0.053).

Conclusion

A combined TBW and body composition-tailored CM protocol in chest CT resulted in more homogenous enhancement and fewer outliers compared to a fixed-volume protocol.

Advances in knowledge

This is, to our knowledge, the first study to investigate the impact of various body compositions on contrast medium enhancement in chest CT.

Optimal Abdominal CT Image Quality in Non-Lean Patients: Customization of CM Injection Protocols and Low-Energy Acquisitions

We compared the image quality of abdominopelvic single-energy CT with 100 kVp (SECT-100 kVp) and dual-energy CT with 65 keV (DECT-65 keV) obtained with customized injection protocols to standard abdominopelvic CT scans (SECT-120 kVp) with fixed volumes of contrast media (CM). We retrospectively included 91 patients (mean age, 60.7 ± 15.8 years) with SECT-100 kVp and 83 (mean age, 60.3 ± 11.7 years) patients with DECT-65 keV in portovenous phase. Total body weight-based customized injection protocols were generated by a software using the following formula: patient weight (kg) × 0.40/contrast concentration (mgI/mL) × 1000. Patients had a prior abdominopelvic SECT-120 kVp with fixed injection. Iopamidol-370 was administered for all examinations. Quantitative and qualitative image quality comparisons were made between customized and fixed injection protocols. Compared to SECT-120 kVp, customized injection yielded a significant reduction in CM volume (mean difference = 9-12 mL; p ≤ 0.001) and injection rate (mean differences = 0.2-0.4 mL/s; p ≤ 0.001) in all weight categories. Improvements in attenuation, noise, signal-to-noise and contrast-to-noise ratios were observed for both SECT-100 kVp and DECT-65 keV compared to SECT-120 kVp in all weight categories (e.g., pancreas DECT-65 keV, 1.2-attenuation-fold increase vs. SECT-120 kVp; p < 0.001). Qualitative scores were ≥4 in 172 cases (98.8.4%) with customized injections and in all cases with fixed injections (100%). These findings suggest that customized CM injection protocols may substantially reduce iodine dose while yielding higher image quality in SECT-100 kVp and DECT-65 keV abdominopelvic scans compared to SECT-120 kVp using fixed CM volumes.

CT pulmonary angiography: optimising acute thoracic imaging by fixed-timing contrast medium delivery with a modified breathing instruction

AIM

To compare the thoracic vascular opacification achieved using the standard bolus-tracking protocol (BTP) with a fixed-timing protocol (FTP) with a modified breathing instruction during computed tomography pulmonary angiography (CTPA) examinations.

MATERIALS AND METHODS

A single-centre review of CTPA examinations performed between July 2018 and January 2019 using the BTP or FTP and weight-based contrast dosing of 20 mg iodine/kg body weight/s for 20 seconds at 100 kV tube potential. Radiodensity (in Hounsfield units) was analysed in the right ventricle, main pulmonary artery (MPA), left atrium, left ventricle, and ascending and descending thoracic aorta (DTA). A p-value of <0.05 was considered significant.

RESULTS

Of 782 examinations, 88 BTP and 90 FTP examinations were included. Mean attenuation of the MPA was similar in the FTP (396 ± 106 HU) and BTP (362 ± 119 HU; p=0.06); however, good-quality (≥250 HU) MPA opacification was achieved in more FTP examinations (87/90, 96.7%) compared to the BTP (73/88, 82.9%; p=0.002). Mean attenuation of the DTA was better in the FTP (325 ± 72 HU) than the BTP (228 ± 75 HU; p <0.0001), with good-quality opacification (≥250 HU) in 76/90 (84.4%) FTP examinations compared with 36/88 (40.9%) BTP examinations (p <0.001).

CONCLUSION

The FTP achieves better opacification of the MPA and DTA compared to the BTP.

Evaluation of the Practice of Performing Abdominal CT Scan with Manually Administered Fixed Dose of Contrast in Achieving Adequate Hepatic Enhancement: An Institutional-Based Cross-Sectional Study

Background

Intravenous (IV) iodine-based contrast agents are administered during computed tomography (CT) examination to enhance the density differences between lesions and surrounding parenchyma, which is important for lesion characterization, and to demonstrate vascular anatomy and vessel patency. Quality of contrast enhancement has a significant influence on diagnostic interpretation and subsequent management. In this study, we assessed the quality of portal venous phase abdominal CT scans performed with a manual injection of a fixed dose of contrast, which is the routine practice at Tikur Anbessa Specialized Hospital (TASH). The effect of age and sex was also assessed.

Method

A hospital-based retrospective review was performed to identify patients who have had a precontrast and postcontrast abdominal CT scan from November 4, 2020, to September 30, 2022. All patients with abdominal CT scans having precontrast and portal venous phase scans were included in the study. All CT scans were reviewed by the principal investigator and the quality of contrast enhancement was assessed.

Results

In this study, there were a total of 379 patients. The mean hepatic attenuations in precontrast and portal venous phase scans were 59.05 ± 6.69 HU and 103.73 ± 12.84 HU. The proportion of scans with less than 50 HU enhancement was 68% (n = 258). There was a significant association between age and sex with contrast enhancement.

Conclusion

The hepatic contrast enhancement pattern of abdominal CT scan at the study institution reveals a concerning degree of image quality. This is evidenced by the high number of suboptimal contrast enhancement indices and the highly variable enhancement patterns across different patients. This can have a negative impact on the diagnostic performance of CT imaging and can adversely affect the management. Furthermore, both sex and age affect the pattern of enhancement.

Hepatic enhancement at computed tomography: is there a dependence on body weight past institutional contrast dosing limits?

BACKGROUND

Although described in product monographs, the maximum contrast media (CM) dose at computed tomography (CT) varies among institutions.

PURPOSE

To investigate whether an upper limit of 40 g of iodine in women and 50 g in men is sufficient or if there is a body weight (BW) dependence of mean hepatic enhancement (MHE) beyond those thresholds.

MATERIAL AND METHODS

At our institution, CM injection duration is fixed to 30 s and dosed 600 mg iodine/kg up to 40 g in women and 50 g in men. Pre- and post-contrast hepatic attenuation values (HU) were retrospectively obtained in 200 women and 200 men with glomerular filtration rate >45 mL/min undergoing 18-flurodeoxyglucose PET-CT (18F-FDG PET-CT) of which half weighed below and half above those dose thresholds using iodixanol 320 mg iodine/mL or iomeprol 400 mg iodine/mL. The correlation between BW and MHE was assessed by simple linear regression.

RESULTS

Weight range was 41-120 kg in women and 47-137 kg in men. There was no significant relationship between MHE and BW in women receiving <40 g (r = -0.05, P = 0.63) or in men receiving <50 g (r = 0.18, P = 0.07). Above those thresholds there was an inverse relationship (r = -0.64, P<0.001 in women and r = -0.30, P<0.002 in men). There was no apparent upper limit where the dependence of hepatic MHE on BW decreased. Hepatosteatosis limited MHE.

CONCLUSION

Adjusting CM to BW diminishes the dependence of MHE on BW. There was no apparent upper limit for the relationship between BW and MHE in heavier patients at CM-enhanced CT.

Variation in aorta attenuation in contrast-enhanced CT and its implications for calcification thresholds

Background

CT contrast media improves vessel visualization but can also confound calcification measurements. We evaluated variance in aorta attenuation from varied contrast-enhancement scans, and quantified expected plaque detection errors when thresholding for calcification.

Methods

We measured aorta attenuation (AoHU) in central vessel regions from 10K abdominal CT scans and report AoHU relationships to contrast phase (non-contrast, arterial, venous, delayed), demographic variables (age, sex, weight), body location, and scan slice thickness. We also report expected plaque segmentation false-negative errors (plaque pixels misidentified as non-plaque pixels) and false-positive errors (vessel pixels falsely identified as plaque), comparing a uniform thresholding approach and a dynamic approach based on local mean/SD aorta attenuation.

Results

Females had higher AoHU than males in contrast-enhanced scans by 65/22/20 HU for arterial/venous/delayed phases (p < 0.001) but not in non-contrast scans (p > 0.05). Weight was negatively correlated with AoHU by 2.3HU/10kg but other predictors explained only small portions of intra-cohort variance (R² < 0.1 in contrast-enhanced scans). Average AoHU differed by contrast phase, but considerable overlap was seen between distributions. Increasing uniform plaque thresholds from 130HU to 200HU/300HU/400HU produces respective false-negative plaque content losses of 35%/60%/75% from all scans with corresponding false-positive errors in arterial-phase scans of 95%/60%/15%. Dynamic segmentation at 3SD above mean AoHU reduces false-positive errors to 0.13% and false-negative errors to 8%, 25%, and 70% in delayed, venous, and arterial scans, respectively.

Conclusion

CT contrast produces heterogeneous aortic enhancements not readily determined by demographic or scan protocol factors. Uniform CT thresholds for calcified plaques incur high rates of pixel classification errors in contrast-enhanced scans which can be minimized using dynamic thresholds based on local aorta attenuation. Care should be taken to address these errors and sex-based biases in baseline attenuation when designing automatic calcification detection algorithms intended for broad use in contrast-enhanced CTs.

A quality-improvement project to enhance systemic arterial contrast opacification in CT for trans-catheter aortic valve implantation

AIM

To assess improvement in arterial opacification by optimising the contrast medium dosing protocol for computed tomography (CT) prior to trans-catheter aortic valve implantation (TAVI).

MATERIALS AND METHODS

A wide variation in arterial opacification was observed in the initial CT TAVI protocol (standard protocol). The practice was optimised by considering the time required for the examination and optimising contrast medium flux. This became the optimised protocol with a 30-second contrast medium bolus of iodine flux 15-19 mg iodine/kg body weight/second (mg/kg/s). Attenuation (mean HU) in (a) the ascending aorta (gated systolic acquisition) and (b) the ascending, descending thoracic (at carina), infra-renal abdominal aorta, and right common iliac artery (non-gated acquisition) was measured. Thirty-one sequential optimised examinations were compared to 31 prior standard protocol examinations.

RESULTS

There was no difference between the standard and optimised groups regarding age, sex, weight, body mass index (BMI), or voltage. The mean bolus durations were 24.9±4.4 seconds for the standard and 30±0.3 seconds for the optimised protocols (p<0.001). Although there was no difference in the attenuation in the gated ascending aorta (p>0.99), there was improvement at all other anatomical points in the non-gated examinations of the optimised protocol (p<0.002).

CONCLUSION

Optimising contrast medium flux and matching bolus duration to the CT technology dramatically improves the vascular access component of TAVI planning and provides a reliable method to achieve objectively enhanced arterial opacification. This work highlights how to obtain good arterial contrast medium opacification in haemodynamically fragile patients without excessive contrast medium volumes.

Contrast medium protocols in routine chest CT: a survey study

BACKGROUND

Administration of contrast medium (CM) is an important image quality factor in computed tomography (CT) of the chest. There is no clear evidence or guidelines on CM strategies for chest CT, thus a consensus approach is needed.

PURPOSE

To survey the potential impact on differences in chest CT protocols, with emphasis on strategies for the administration of CM.

MATERIAL AND METHODS

A total of 170 respondents were included in this survey, which used two different approaches: (i) an online survey was sent to the members of the European Society of Thoracic Imaging (ESTI); and (ii) an email requesting a copy of their CT protocol was sent to all hospitals in Norway, and university hospitals in Sweden and Denmark. The survey focused on factors affecting CM protocols and enhancement in chest CT.

RESULTS

The overall response rate was 24% (n = 170): 76% of the respondents used a CM concentration of ≥350 mgI/mL; 52% of the respondents used a fixed CM volume strategy. Fixed strategies for injection rate and delay were also the most common approach, practiced by 73% and 57% of the respondents, respectively. The fixed delay was in the range of 20-90 s. Of the respondents, 56% used flexible tube potential strategies (kV).

CONCLUSION

The chest CT protocols and CM administration strategies employed by the respondents vary widely, affecting the image quality. The results of this study underline the need for further research and consensus guidelines related to chest CT.

A Metric for Quantification of Iodine Contrast Enhancement (Q-ICE) in Computed Tomography

BACKGROUND

Poor contrast enhancement is related to issues with examination execution, contrast prescription, computed tomography (CT) protocols, and patient conditions. Currently, our community has no metric to monitor true enhancement on routine single-phase examinations because this requires knowledge of both pre- and postcontrast CT number.

PURPOSE

We propose an automatable solution to quantifying contrast enhancement without requiring a dedicated noncontrast series.

METHODS

The difference in CT number between a target region in an enhanced and unenhanced image defines the metric "quantification of iodine contrast enhancement" (Q-ICE). Quantification of iodine contrast enhancement uses the noncontrast bolus tracking baseline image from routine abdominal examinations, which mitigates the need for a dedicated noncontrast series. We applied this method retrospectively to 312 patient livers from 2 sites between 2017 and 2020. Each site used a weight-based contrast injection protocol for weights 60 to 113 kg and a constant volume less than 60 kg and greater than 113 kg. Hypothesis testing was performed to compare Q-ICE between sites and detect Q-ICE dependence on weight and kilovoltage (kV).

RESULTS

Mean Q-ICE differed between sites (P = 0.004) by 4.96 Hounsfield unit with 95% confidence interval (1.63-8.28), albeit this difference was roughly 2 times smaller than the SD in Q-ICE across patients at a single site. For patients between 60 and 113 kg, we did not observe evidence of Q-ICE varying with patient weight (P = 0.920 and 0.064 for 120 and 140 kV, respectively). The Q-ICE did vary with patient weight for patients less than 60 kg (P = 0.003) and greater than 113 kg (P = 0.04). We observed a roughly 10 Hounsfield unit reduction in Q-ICE liver for patients scanned with 140 versus 120 kV. We observed several underenhancing examinations with an arterial phase appearance motivating our CT protocol optimization team to consider increasing the delay for slowly enhancing patients.

CONCLUSIONS

A quality metric for quantifying CT contrast enhancement was developed and suggested tangible opportunities for quality improvement and potential financial savings.

Contrast media injection protocol for portovenous phase abdominal CT: does a fixed injection duration improve hepatic enhancement over a fixed injection rate?

PURPOSE

To assess whether a fixed contrast media (CM) injection duration improves the magnitude and inter-patient variability in hepatic enhancement over a fixed injection rate.

METHODS

Outpatients who underwent portovenous phase abdominal CT (fixed duration, February-November 2018; fixed rate, January-July 2020) with 1.22 mL/kg iohexol 350 were included. Subjects with liver, kidney or heart disease were excluded. The number of subjects and injection protocols were as follows: fixed duration arm, 56 women, 60 men, 35 s injection duration; fixed rate arm, 66 women, 62 men, 3 mL/s injection rate. Liver attenuation measurements were obtained from regions of interest on pre- and post-contrast images. Mean hepatic enhancement (MHE) and MHE normalized to iodine dose (MHE/I) were compared (unpaired t-tests and F-tests).

RESULTS

There was no statistically significant difference in age, weight, body mass index or CM dosing (p > 0.05). Enhancement indices were significantly lower in the fixed rate group as compared to the fixed duration group, as follows: MHE, 50.0 ± 12 vs. 54.8 ± 11 HU (p = 0.001); and MHE/I, 1.53 ± 0.43 vs. 1.66 ± 0.51 HU/g, (p = 0.04). However, there was no significant difference in the variances of MHE (p = 0.51) and MHE/I (p = 0.08).

CONCLUSION

A fixed CM injection duration yields a greater magnitude in hepatic enhancement indices than a fixed injection rate. Inter-patient variability in hepatic enhancement indices do not significantly differ between the two injection protocols.

Optimization of contrast medium volume for abdominal CT in oncologic patients: prospective comparison between fixed and lean body weight-adapted dosing protocols

Background

Patient body size represents the main determinant of parenchymal enhancement and by adjusting the contrast media (CM) dose to patient weight may be a more appropriate approach to avoid a patient over dosage of CM. To compare the performance of fixed-dose and lean body weight (LBW)-adapted contrast media dosing protocols, in terms of image quality and parenchymal enhancement.

Results

One-hundred cancer patients undergoing multiphasic abdominal CT were prospectively enrolled in this multicentric study and randomly divided in two groups: patients in fixed-dose group (n = 50) received 120 mL of CM while in LBW group (n = 50) the amount of CM was computed according to the patient’s LBW. LBW protocol group received a significantly lower amount of CM (103.47 ± 17.65 mL vs. 120.00 ± 0.00 mL, p < 0.001). Arterial kidney signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) and pancreatic CNR were significantly higher in LBW group (all p ≤ 0.004). LBW group provided significantly higher arterial liver, kidney, and pancreatic contrast enhancement index (CEI) and portal venous phase kidney CEI (all p ≤ 0.002). Significantly lower portal vein SNR and CNR were observed in LBW-Group (all p ≤ 0.020).

Conclusions

LBW-adapted CM administration for abdominal CT reduces the volume of injected CM and improves both image quality and parenchymal enhancement.

Customised weight-based volume contrast media protocol in CT of chest, abdomen and pelvis examination

INTRODUCTION

Fixed volume (FV) contrast media administration during CT examination is the standard practice in most healthcare institutions. We aim to validate a customised weight-based volume (WBV) method and compare it to the conventional FV methods, introduced in a regional setting.

METHODS

220 patients underwent CT of the chest, abdomen and pelvis (CAP) using a standard FV protocol, and subsequently, a customised 1.0 mL/kg WBV protocol within one year. Both image sets were assessed for contrast enhancement using CT attenuation at selected regions-of-interest (ROIs). The visual image quality was evaluated by three radiologists using a 4-point Likert scale. Quantitative CT attenuation was correlated with the visual quality assessment to determine the HU's enhancement indicative of the image quality grades. Contrast media usage was calculated to estimate cost-savings from both protocols.

RESULTS

Mean patient age was 61 ± 14 years, and weight was 56.1 ± 8.7 kg. FV protocol produced higher contrast enhancement than WBV, p < 0.001. CT images' overall contrast enhancement was negatively correlated with body weight for FV protocol while the WBV protocol produced more consistent enhancement across different body weight. More than 90% of the images from both protocols were graded "Excellent". WBV protocol also enabled a 28% cost reduction with cost savings of US$1238.

CONCLUSION

The customised WBV protocol produced CT images which were comparable to FV protocol for CT CAP examinations. A median CT value of 100 HU can be an indicator of good image quality for the WBV protocol.

Personalized computed tomography - Automated estimation of height and weight of a simulated digital twin using a 3D camera and artificial intelligence

PURPOSE

 The aim of this study was to develop an algorithm for automated estimation of patient height and weight during computed tomography (CT) and to evaluate its accuracy in everyday clinical practice.

MATERIALS AND METHODS

 Depth images of 200 patients were recorded with a 3D camera mounted above the patient table of a CT scanner. Reference values were obtained using a calibrated scale and a measuring tape to train a machine learning algorithm that fits a patient avatar into the recorded patient surface data. The resulting algorithm was prospectively used on 101 patients in clinical practice and the results were compared to the reference values and to estimates by the patient himself, the radiographer and the radiologist. The body mass index was calculated from the collected values for each patient using the WHO formula. A tolerance level of 5 kg was defined in order to evaluate the impact on weight-dependent contrast agent dosage in abdominal CT.

RESULTS

 Differences between values for height, weight and BMI were non-significant over all assessments (p > 0.83). The most accurate values for weight were obtained from the patient information (R² = 0.99) followed by the automated estimation via 3D camera (R² = 0.89). Estimates by medical staff were considerably less precise (radiologist: R² = 0.78, radiographer: R² = 0.77). A body-weight dependent dosage of contrast agent using the automated estimations matched the dosage using the reference measurements in 65 % of the cases. The dosage based on the medical staff estimates would have matched in 49 % of the cases.

CONCLUSION

 Automated estimation of height and weight using a digital twin model from 3D camera acquisitions provide a high precision for protocol design in computer tomography.

KEY POINTS

  · Machine learning can calculate patient-avatars from 3D camera acquisitions.. · Height and weight of the digital twins are comparable to real measurements of the patients.. · Estimations by medical staff are less precise.. · The values can be used for calculation of contrast agent dosage..

CITATION FORMAT

· Geissler F, Heiß R, Kopp M et al. Personalized computed tomography - Automated estimation of height and weight of a simulated digital twin using a 3D camera and artificial intelligence. Fortschr Röntgenstr 2021; 193: 437 - 445.

Weight-Adjusted Contrast Administration in the Computed Tomography Evaluation of Pulmonary Embolism

INTRODUCTION

Computed tomography pulmonary angiogram (CTPA) is widely considered the gold standard for diagnosis of pulmonary embolism (PE) with previous studies demonstrating high sensitivity and specificity. Despite this, nondiagnostic and indeterminate CTPA rates of 5%-26% remain a concern. As part of a continuing quality assurance program, a new weight-adjusted contrast dose and increased administration rate CTPA protocol was studied with an aim to improve diagnostic accuracy of PE evaluation.

METHODS

A total of 2,398 CTPA examinations were reviewed to assess pulmonary arterial enhancement and PE yield in this retrospective study. Between 1 August 2014 and 1 August 2015, 1,133 patients received a fixed-volume (60 mL) contrast dose technique at 4 mL/s (protocol A). A new protocol was then implemented as part of a continuing quality assurance program. Between 15 September 2015 and 15 September 2016, 1,265 patients received a weight-adjusted contrast dose (1 mL/kg) and increased administration rate (5 mL/s) CTPA technique (protocol B). Studies were classed into categories based on quality of study; diagnostic: HU > 211, nondiagnostic: HU < 211 and PE yield; positive, negative, and indeterminate. These variables were compared with cross-sectional surface area to assess the relationship between patient habitus, CTPA diagnostic quality, and PE yield.

RESULTS

A weight-adjusted contrast dose and increased administration rate CTPA protocol (protocol B) resulted in a significant increase in mean PA enhancement (P < .0001), 55.23% decrease in nondiagnostic studies and 43.04% decrease in indeterminate studies. Protocol B demonstrated increased positive and negative CTPA rates with decreased indeterminate rates from 12.38% to 7.04%. Comparison with cross-sectional area demonstrated significant increase in proportion of diagnostic studies and reduction in nondiagnostic and indeterminate CTPAs using protocol B in obese patients.

CONCLUSIONS

A weight-adjusted contrast dose and increased administration rate CTPA protocol can significantly increase PA enhancement, especially in obese patients, resulting in greater high-quality and fewer nondiagnostic and indeterminate CTPA examinations. A CTPA protocol with a higher rate of conclusive examinations can provide greater confidence in PE evaluation for reporting radiologists and accurate clinical decision-making pathways for referring physicians.

Dosing Iodinated Contrast Media According to Lean Versus Total Body Weight at Abdominal CT: A Stratified Randomized Controlled Trial

RATIONALE AND OBJECTIVES

To compare the magnitude and interpatient variability in normalized mean hepatic enhancement (MHE) indices when dosing contrast media (CM) according to total body weight (TBW) and lean body weight (LBW).

MATERIALS AND METHODS

This ethics-approved stratified randomized controlled study allocated 280 outpatients for abdominal Computed Tomography (CT) between February-November 2018 to TBW- or LBW-dosing using computer-generated tables. CTs were acquired in portal venous phase after fixed 35-second injection of Iohexol 350. Patients with missing precontrast image, incorrect dose, or chronic kidney, liver or heart disease were excluded. The number of included patients and CM doses were: TBW arm, 51 women and 60 men, 1.22 mL/kg; LBW arm, 59 women, 1.66 mL/kg LBW, and 59 men, 1.52 mL/kg LBW. Liver attenuations were obtained from regions of interest. Values and standard deviations in MHE indices normalized to iodine dose (MHE/I) and iodine dose per kg TBW (aMHE = MHE/[I/TBW]) were compared (unpaired t tests and F-tests).

RESULTS

Cohorts were similar in age, sex, TBW, and LBW. TBW groups received more CM than LBW groups: men, 106.5 ± 20 versus 98.4 ± 11 mL, p = 0.007; women, 93.7 ± 20 versus 77.5 ± 11 mL, p < 0.0001. TBW and LBW groups showed no significant difference in MHE/I (women, 1.75 ± 0.5 versus 1.86 ± 0.6 HU/g, p = 0.31; men, 1.53 ± 0.4 versus 1.52 ± 0.4 HU/g, p = 0.90) or aMHE (women, 0.03 ± 0.01 versus 0.03 ± 0.01 HU/g/kg, p = 0.25; men, 0.02 ± 0.01 versus 0.02 ± 0.01 HU/g/kg, p = 0.52). Variances in MHE/I and aMHE were not significantly different for all groups (p > 0.05).

CONCLUSION

TBW- and LBW-based CM dosing yield a similar magnitude and interpatient variability in normalized MHE indices at routine abdominal CT.

Venous-phase chest CT with reduced contrast medium dose: Utilization of spectral low keV monoenergetic images improves image quality

PURPOSE

Intravenous contrast administration is crucial in many CT examinations but also poses a potential risk to the patient. Monoenergetic images (MonoE) of dual-energy CT systems can virtually increase iodine attenuation and might improve image quality (IQ) if contrast dose is reduced. In this study, we investigated the influence of MonoE on lymph node (LN) delineation and IQ in chest CT examinations with significantly reduced contrast dose (50 %) of a novel dual-layer CT (DLCT).

METHOD

30 patients with clinically indicated reduced contrast dose underwent venous-phase chest DLCT scans. Conventional polyenergetic (PolyE) and MonoE images at 40 keV were calculated. The contrast difference of hilar lymph nodes (LN-CD) to the adjacent right pulmonary artery, their signal-to-noise (SNR) and contrast-to-noise-ratio (CNR) were determined. Subjective IQ was evaluated by 2 readers with respect to LN delineation and overall contrast enhancement (CE) using a 5-point-Likert-scale.

RESULTS

LN-CD, SNR and CNR were significantly higher in MonoE than in PolyE images (LN-CD 92.3 ± 37.9 vs. 33.1 ± 14.5 HU, SNR 8.4 ± 3.4 vs. 4.0 ± 1.2, CNR 9.2 ± 6.3 vs. 2.6 ± 1.5; all p < 0.01). The LN delineation (3.7 ± 0.9 vs.1.8 ± 0.7; p < 0.01) and the CE (3.9 ± 0.7 vs. 2.3 ± 0.7; p < 0.01) were rated significantly better for MonoE than for PolyE images. There was no MonoE examination classified as non-diagnostic.

CONCLUSIONS

Subjective and objective IQ parameters can be significantly improved for venous-phase chest CT examinations with reduced contrast doses by utilization of low-keV MonoE reconstructions. All MonoE images provided sufficient overall CE and therefore reduced contrast doses might be considered in a wider range of DLCT examinations and patients.

Implementation of patient-tailored contrast volumes based on body surface area and heart rate harmonizes contrast enhancement and reduces contrast load in small patients in portal venous phase abdominal CT

PURPOSE

The aim of this study was to evaluate the impact of a patient-tailored contrast volume protocol on portal venous phase abdominal CT-images compared to a fixed volume protocol in daily radiological practice.

METHOD

Data of 77 patients who underwent two contrast-enhanced CT-examinations were collected. The first examination was performed with a fixed contrast volume (95 ml), the follow-up examination was performed with a patient-tailored contrast volume based on patient's BSA and heart rate. The patient-tailored volume was calculated by a software application integrated in the interface of the injection pump. Two independent radiologists assessed subjective and objective image quality. Differences in enhancement and contrast volumes between both protocols were analysed.

RESULTS

Despite a significant contrast volume reduction in women and in patients with low to normal BMI, enhancement was more consistent over different BMI-categories in the patient-tailored contrast volume protocol and there was no significant difference in subjective image quality between both injection protocols.

CONCLUSIONS

A patient-tailored contrast volume protocol based on BSA and heart rate can be considered in daily radiological practice to decrease contrast volumes in women and in low to normal BMI patients and to achieve more consistent contrast enhancement across different BMI-categories in venous phase abdominal CT.

Comparison of Abdominal Computed Tomographic Enhancement and Organ Lesion Depiction Between Weight-Based Scanner Software Contrast Dosing and a Fixed-Dose Protocol in a Tertiary Care Oncologic Center

OBJECTIVE

This study aimed to evaluate the quality of enhancement and solid-organ lesion depiction using weight-based intravenous (IV) contrast dosing calculated by injector software versus fixed IV contrast dose in oncologic abdominal computed tomographic (CT) examinations.

METHODS

This institutional review board-exempt retrospective cohort study included 134 patients who underwent single-phase abdominal CT before and after implementation of weight-based IV contrast injector software. Patient weight, height, body mass index, and body surface area were determined. Two radiologists qualitatively assessed examinations (4 indicating markedly superior to -4 indicating markedly inferior), and Hounsfield unit measurements were performed.

RESULTS

Enhancement (estimated mean, -0.05; 95% confidence interval [CI], -0.19 to 0.09; P = 0.46) and lesion depiction (estimated mean, -0.01; 95% CI, -0.10 to 0.07; P = 0.79) scores did not differ between CT examinations using weight-based IV contrast versus fixed IV contrast dosing when a minimum of 38.5 g of iodine was used. However, the scores using weight-based IV contrast dosing were lower when the injector software calculated and delivered less than 38.5 g of iodine (estimated mean, -0.81; 95% CI, -1.06 to -0.56; P < 0.0001). There were no significant differences in measured Hounsfield units between the CT examinations using weight-based IV contrast dosing versus fixed IV contrast dosing.

CONCLUSIONS

Oncologic CT image quality was maintained or improved with weight-based IV contrast dosing using injector software when using a minimum amount of 38.5 g of iodine.

An Individually Optimized Protocol of Contrast Medium Injection in Enhanced CT Scan for Liver Imaging

Objective

To investigate the effectiveness of a new individualized contrast medium injection protocol for enhanced liver CT scan.

Methods

324 patients who underwent plain and dual phase enhanced liver CT were randomly assigned to 2 groups: G1 (n = 224, individualized contrast medium injection protocol); G2 (n = 100, standard contrast medium injection with a dose of 1.5 ml/kg). CT values and ΔHU (CT values difference between plain and enhanced CT) of liver parenchyma and tumor-liver contrast (TLC) during hepatic arterial phase (HAP) and portal venous phase (PVP) and contrast medium dose were measured. The tumor conspicuity of hepatocellular carcinoma (HCC) between two groups was independently evaluated by two radiologists.

Results

The mean contrast medium dose of G1 was statistically lower than that of G2. There were no significantly statistical differences in CT values and ΔHU of liver parenchyma during HAP, TLC values during HAP, and PVP between two groups. The CT values and ΔHU of liver parenchyma during PVP of G2 were significantly higher than those of G1. Two independent radiologists were both in substantial conformity in grading tumor conspicuity.

Conclusion

Using the individually optimized injection protocol might reduce contrast medium dose without impacting on the imaging quality in enhanced liver CT.